The National Comprehensive Cancer Network® (NCCN) has published a set of
guidelines for patients with
Waldenström’s macroglobulinemia/ lymphoplasmacytic lymphoma (WM/LPL).
This resource describes what WM is and how it develops,
explains testing for WM, and provides information on the treatment of
primary, relapsed, and refractory WM.
NCCN Guidelines for Patients are adaptations of the
NCCN Clinical Practice Guidelines in Oncology.
The NCCN also publishes Quick Guide™ sheets, which are 1-page summaries of key points in the patient guidelines.
Both patient resources are available free of charge at NCCN.org/patients as well as on the NCCN Patient Guides for Cancer mobile app.
“The treatment approach to patients with Waldenström’s macroglobulinemia has significantly changed in the recent years with better understanding of the disease biology and its natural history and availability of new drugs, allowing for a more individualized approach,” said Shaji Kumar, MD, of the Mayo Clinic in Rochester, Minnesota.
“The revised guidelines reflect these changes and will be a valuable guide for patients in shared decision-making with their oncologists.”
NCCN Guidelines for Patients are based on the same clinical practice guidelines used by healthcare professionals to determine the best way to treat a patient with cancer.
Each resource features expert guidance from US cancer centers designed to help people living with cancer talk to their physicians about the best treatment options for their disease.
The Guidelines for Patients and Quick Guide sheets are written in plain language and include patient-friendly elements, such as “questions to ask your doctor,” a glossary of terms, and medical illustrations of anatomy, tests, and treatment.
NCCN currently offers NCCN Guidelines for Patients covering the following topics: brain, breast, colon esophageal, kidney, non-small cell lung, ovarian, pancreatic, prostate, and stomach cancers; acute lymphoblastic leukemia; adolescents and young adults with cancer; chronic lymphocytic leukemia; chronic myelogenous leukemia; Hodgkin lymphoma; lung cancer screening; malignant pleural mesothelioma; melanoma; multiple myeloma; nausea and vomiting; non-Hodgkin lymphomas; soft tissue sarcoma; and WM/LPL.
